Tumor Hospital of Gansu Province

Lanzhou, China

Tumor Hospital of Gansu Province

Lanzhou, China
Time filter
Source Type

Yang T.-M.,Xi'an Jiaotong University | Qi S.-N.,Lanzhou University | Zhao N.,Lanzhou University | Yang Y.-J.,First Hospital of the PLA | And 3 more authors.
Apoptosis | Year: 2013

Previous study has found that a new nitroxyl spin-labeled derivative of podophyllotoxin, 4-[4″-(2″,2″,6″,6″-tetramethyl- 1″-piperidinyloxy)amino]-4′-demethyl-epipodophyllotoxin (GP7), can induce apoptosis in human leukemia cells. However, there have been no studies about the effects of GP7 on osteosarcoma (OS) cells. Here, we observed the anti-OS effects of GP7 in mouse and human OS cells with the comparison of etoposide. GP7 and etoposide inhibited the proliferation of a panel of mouse and human OS cells in a concentration- or time-dependent manner, and the inhibitory effect of GP7 on the proliferation of mouse LM8 or human U2OS cells was 1.28- or 1.35-fold higher than that of etoposide. GP7 or etoposide augmented the anti-OS effects of methotrexate, adriamycin, cisplatin, or their combination, and the combined inhibitory effects of GP7 with MTX on the proliferation of LM8 cells was higher than those of etoposide with MTX. GP7 arrested the cell cycle in S phase but etoposide in G2/M phase. GP7 or etoposide induced sub-G1 peak, apoptotic DNA fragmentation, activations of caspase-3, -8, -9, and DNA fragmentation factor, downregulation of Bcl-2 and Bcl-xL, upregulation of Bax and Bak, and cytochrome-c release from mitochondria in both mouse and human OS cells. GP7 or etoposide also induced endonuclease G translocation from mitochondria into cytosol in mouse cells. GP7- or etoposide-induced apoptotic DNA fragmentation of human OS cells was inhibited by the pan caspase inhibitor and caspase-9 inhibitor, not by caspase-8 inhibitor whereas it was not inhibited by the pan caspase inhibitor in mouse OS cells. Our findings indicate that GP7 is effective against mouse and human OS cells in vitro. The apoptotic DNA fragmentation in mouse OS cells may be mediated by caspase-independent pathway with the involvement of endonuclease G whereas in human OS cells by caspase-9-dependent pathway downstream of the cytochrome-c-initiated caspase cascade. © 2013 Springer Science+Business Media New York.

Pan Y.,Lanzhou University | Yang K.,Lanzhou University | Shi X.,Gansu Rehabilitaition Center Hospital | Liang H.,Tianjin University | And 2 more authors.
Evidence-based Complementary and Alternative Medicine | Year: 2015

Objective. Tai Chi Chuan (TCC) is a form of aerobic exercise that may be an effective therapy for improving psychosomatic capacity among breast cancer survivors. This meta-analysis analyzed the available randomized controlled trials (RCTs) on the effects of TCC in relieving treatment-related side effects and quality of life in women with breast cancer. Methods. RCTs were searched in PubMed, Embase, Web of Science, and Cochrane Library through April 2014. Data were analyzed on pathology (pain, interleukin-6, and insulin-like growth factor 1), physical capacity (handgrip, limb physical fitness, and BMI), and well-being (physical, social, emotional, and general quality of life). Results. Nine RCTs, including a total of 322 breast cancer patients, were examined. Compared with control therapies, the pooled results suggested that TCC showed significant effects in improving handgrip dynamometer strength, limb elbow flexion (elbow extension, abduction, and horizontal adduction). No significant differences were observed in pain, interleukin-6, insulin-like growth factor, BMI, physical well-being, social or emotional well-being, or general health-related quality of life. Conclusion. The short-term effects of TCC may have potential benefits in upper limb functional mobility in patients with breast cancer. Additional randomized controlled trials with longer follow-up are needed to provide more reliable evidence. © 2015 Yuanqing Pan et al.

Wang B.-B.,Gansu College of Traditional Chinese Medicine | Zhang Q.-N.,Tumor Hospital of Gansu Province | Tian J.-H.,Lanzhou University
Journal of Practical Oncology | Year: 2014

Objective: To systematically evaluate the efficacy and safety of temozolomide combined with whole brain radiotherapy for brain metastasis of malignant tumors.Methods: PubMed, The Cochrane Library, Web of Knowledge, CBM, CNKI and WanFang databases were searched to collect randomized clinical trials (RCTs) on brain metastasis of malignant tumors treated with temozolomide plus whole brain radiotherapy vs whole brain radiotherapy alone from inception to March 1st, 2014. References of included studies were also retrieved. Two reviewers independently screened studies according to exclusion and inclusion criteria, extracted data and assessed methodological quality. Meta-analysis was performed using RevMan 5.2 software.Results: Ten trials were included involving 584 patients. The results of meta-analysis showed that compared with radiotherapy alone group, temozolomide combined with radiotherapy improved short-term effects (OR=4.27, 95% CI: 2.67~6.83, P<0.00001), yet it increased the incidence of gastrointestinal reactions(OR=1.78, 95% CI: 1.11~2.85, P=0.02). No significant difference was observed in the incidences of headache(OR=1.34, 95% CI: 0.82~2.18, P=0.24), white blood cell decline(OR=1.41, 95% CI: 0.81~2.44, P=0.22)and platelet decline(OR=2.26, 95% CI: 0.82~6.20, P=0.11)between two groups.Conclusion: Compared with whole brain radiotherapy alone, temozolomide combined with whole brain radiotherapy can improve clinical efficacy for brain metastasis of malignant tumor. ©, 2014, Journal of Practical Oncology, Editorial Board. All right reserved.

Xu T.,Lanzhou University | Chen J.,Lanzhou University | Zhu L.,Tumor Hospital of Gansu Province | Li Z.,Lanzhou University
American Journal of Botany | Year: 2011

Premise of the study: Polymorphic microsatellite loci primers were developed in an alpine plant endemic to the Qinghai-Tibetan Plateau, Aconitum gymnandrum, to investigate its population genetic structure and cryptic speciation. Methods and Results: Using the combined biotin capture method, 16 polymorphic microsatellite loci were identified in 66 individuals from six geographically distant populations of A. gymnandrum. Across all the A. gymnandrum samples, the number of alleles per locus ranged from 4 to 15. Conclusions: These markers will be useful to study population structure and cryptic speciation of A. gymnandrum. © 2011 Botanical Society of America.

Chang H.,Lanzhou University | Shi X.,Tumor Hospital of Gansu Province | Shen W.,Tumor Hospital of Gansu Province | Wang W.,Lanzhou University | Yue Z.,Lanzhou University
Clinica Chimica Acta | Year: 2012

Background: Crystalline morphology and compositions of melamine-associated urinary stones caused by consumption of melamine-contaminated infant formula are reported. Methods: Twelve melamine-associated urinary stone samples were obtained from 12 children aged from 3 to 36. months who were treated in Lanzhou University Second Hospital. The crystalline morphology and compositions of these stone samples were analyzed using a combination of infrared spectrum, SEM and XRD. The presence of melamine in 12 stones was determined by HPLC. Results: Diversity of crystalline morphology in 10 stone samples was revealed by SEM observation. Infrared spectral data revealed that 8 of the 10 stone samples predominantly consisted of the crystal forms of urate: 1 of sodium urate monohydrate, 2 of uricite and 5 of uric acid dihydrate and ammonium urate. However, ammonium magnesium phosphate hexahydrate, ammonium urate and carbonate apatite were also identified in 1 stone sample. The content of melamine in all of the 12 stone samples was determined by HPLC and found to range from 200 to 339,000μg/g. XRD analysis in 6 stone samples showed that amorphous mineral phase was involved in the calculogenesis. Conclusions: Melamine and uric acid are the main possible etiologic factors closely related to melamine-associated urinary stone formation in humans. © 2012 Elsevier B.V.

Liu R.,Lanzhou University | Liu R.,Tumor Hospital of Gansu Province | Wang X.,Tumor Hospital of Gansu Province | Ma B.,Lanzhou University | And 3 more authors.
Anti-Cancer Drugs | Year: 2010

The objective of this study was to assess the clinical efficacy and safety of concomitant or adjuvant tomozolomide with whole-brain irradiation (WBI) in patients with brain metastases. MEDLINE, EMBASE, Cochrane Library, Chinese Biomedical Literature Database were searched to identify relevant original published trails, and the references of eligible studies were manually screened. Randomized controlled trails reported in any language, comparing concomitant or adjuvant temozolomide (TMZ) and WBI with WBI alone in patients with brain metastases, were eligible for inclusion. Two investigators independently assessed the quality of included trials and extracted data. The RevMan 5 software was used for statistical analysis. Four trials involving 280 patients were included. The result showed that the group TMZ+WBI was superior to group WBI in partial response, stable disease, progressive disease, and objective response with the pooled risk ratio value and 95% confidence interval, respectively, 1.89 (1.19-3.02), 0.82 (0.45-1.50), 0.29 (0.10-0.78), and 1.72 (1.32-2.24). The incidence of gastrointestinal symptoms and ≥ grade 3 myelosuppression presented statistical difference, TMZ+WBI group is higher than WBI group, the pooled risk ratio value and 95% confidence interval were 3.75 (1.04-13.44) and 13 (1.75-96.79), respectively. The currently available evidence showed that the combination of TMZ and WBI may moderately improve the response rate, but accordingly increase the incidence of gastrointestinal symptoms and myelosuppression. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Wang J.,Tumor Hospital of Gansu Province
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery | Year: 2011

To introduce the experience of the clinical application of vertical trapezius myocutaneous flap in repairing soft tissue defects after head and neck tumor resection. Between June 2008 and February 2010, 12 cases of soft tissue defect caused by head and neck tumor resection were repaired with vertical trapezius myocutaneous flap. There were 9 males and 3 females with an age range from 32 to 76 years (median, 54 years). Twelve cases including 2 cases of basal cell carcinoma of orbital skin, 2 cases of squamous cell carcinoma of the parotid gland, 2 cases of submandibular gland malignant mixed tumor, 2 cases of metastatic lymph nodes of nasopharyngea carcinoma after radiotherapy, 1 case of squamous cell carcinoma of tongue, and 3 cases of squamous cell carcinoma of occipital skin, and all were classified as TNM stages T3 or T4. The area of soft tissue defect ranged from 13 cm x 6 cm to 25 cm x 13 cm. The vertical trapezius myocutaneous flap ranged from 14 cm x 7 cm to 26 cm x 14 cm and was transferred to repair defect tissue in the homolateral wounds after tumor resection and neck dissection homochronously. The donor sites were sutured directly. All incisions healed primarily without infection. Eleven flaps survived except 1 flap with edge necrosis, which was cured after dressing change. Subcutaneous hematocele and effusion occurred in 2 cases on the back after tube was removed at 7 days postoperatively, and they were cured by sucked and pressured dressing. Eleven patients were followed/up 1-3 years (mean, 2 years). Nine cases had no tumor recurrence and the flaps had satisfactory appearance; the abduction function of shoulder joint were normal. One case of orbit basal cell carcinoma occurred 3 months after operation and 1 case of nasopharyngeal carcinoma died of brain metastasis 12 months after operation. It is an easy and simple therapy to repair head and neck soft tissue defect using the vertical trapezius myocutaneous flap, which can meet the needs of repairing tissue defect of head and neck.

Ma S.H.,Tumor Hospital of Gansu Province
Zhonghua yi xue za zhi | Year: 2011

To explore the clinical features and surgical treatment of tumors associated with Castleman's disease (CD). The clinical profiles of 19 patients with neck giant lymph node hyperplasia were analyzed retrospectively. There were 8 males and 11 females with a median age of 40 years old (range: 7 - 74). The tumor locations were neck (n = 12), neck & mediastinal cavity (n = 2), axillary fossa (n = 2), retroperitoneal area (n = 2) and abdominal cavity (n = 1). Eighteen of them underwent surgical resection of tumor or lymph nodes. All were diagnosed as CD by pathological examinations. There were 16 localized CD (LCD) including hyaline vascular type (HV type, n = 11), mixed type (mix type, n = 4) and plasma cell type-Hodgkin's disease (n = 1). Among 3 multicentric CD (MCD), there were 2 case of plasma cell type (PC type) and 1 case of mixed type (mix type). Long-term survival was achieved in 19 cases among which 1 case of plasma cell type MCD survived for 5 years and underwent a second operation and postoperative chemotherapy of CVP (cyclophosphamide, vincristine & prednisone) regimen for 3 cycles due to recurrence in 2 years and 1 case of plasma cell type LCD-Hodgkin's disease survived for 15 months and underwent a second operation and postoperative chemotherapy of ABVD (adriamycin, bleomycin, vinblastine & dacarbazine)regimen for 6 cycles due to recurrence in 6 months. One case of plasma cell type MCD in abdominal cavity on chemotherapy of CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine & prednisone) regimen for 6 cycles was discharged after a successful management of intestinal obstruction. The major clinical symptom of CD is a gradually enlarging painless mass. Surgical resection of tumor remains the first-line treatment for localized CD and the prognosis is excellent. Multicentric and plasma cell type CDs are prone to recurrence and transformation to lymphoma. And their first-line therapeutic should encompass multi-modality regimens of surgery and adjuvant chemotherapy. However, the clinical prognosis is still poor.

Li K.,Medicine and Science Research Institute of Gansu Province | Du H.,Medicine and Science Research Institute of Gansu Province | Lian X.,Medicine and Science Research Institute of Gansu Province | Yang S.,Tumor Hospital of Gansu Province | And 4 more authors.
BMC Cancer | Year: 2014

Background: Βeta-2-microglobulin (β2-M) has been demonstrated as a growth factor and signaling molecule in breast cancer and leukemia. The purpose of the study is to characterize β2-M expression in molecular subtypes of breast cancer, thereby investigating the mechanism of β2-M action in breast cancer.Methods: β2-M and B-Cell Lymphoma/Leukemia 2 (Bcl-2) transcript expression levels in breast cancer tissue and the corresponding normal tissue were quantified using real-time PCR. The protein expression levels of β2-M, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), tumor protein 53 (p53) and Ki67 were determined by immunohistochemical (IHC) staining. Following silencing of the β2-M by siRNA, the levels of Bcl-2, ER, PR and HER-2 transcripts and the protein expression levels in human breast cancer cells were measured by real-time PCR and western blotting, respectively.Results: The expression of β2-M transcripts demonstrated no significant differences between the four breast cancer molecular subtypes and no significant correlations with age, clinical stage or lymph node metastasis. β2-M transcript expression demonstrated a positive correlation when compared to Bcl-2 transcript expression (P < 0.05). The β2-M protein expression was significantly higher in breast cancer when compared with benign breast tumors (P < 0.01), and have no significant correlation with age, clinical stage or lymph node metastasis. There was a significant difference demonstrated in β2-M protein expression in the four breast cancer molecular subtypes (P < 0.05), and between the ER+ and ER- groups (P < 0.01); however, no significant difference was demonstrated between the HER-2+ and HER-2- groups. β2-M protein expression had a negative correlation with ER protein expression (P < 0.01), a positive correlation with p53 protein expression (P < 0.01), and no correlation with Ki67 protein expression. β2-M silencing significantly inhibited Bcl-2 mRNA expression, but did not inhibit ER, PR and HER-2 mRNA expression in MCF-7 cells (ER+, PR+ and HER-2-). In addition, Bcl-2 and HER-2 mRNA expression were significantly up-regulated in MDA-MB-231 cells (ER-, PR- and HER-2-), which is consistent with the silencing effect seen at the protein level.Conclusions: β2-M expression demonstrated a significant difference in the four breast cancer molecular subtypes, and may be related to apoptosis regulation in breast cancer. © 2014 Li et al.; licensee BioMed Central Ltd.

The aim of this study was to investigate the association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and additional gene-gene interaction with acute lymphoblastic leukemia (ALL) risk. Logistic regression was performed to investigate the association between two single nucleotide polymorphisms (SNPs) within MTHFR gene and ALL risk and additional gene-gene interaction between rs1801133 and rs1801131. The minor allele of rs1801133 and rs1801131 is associated with decreased ALL risk, OR (95% CI) were 0.61 (0.38-0.89), and 0.68 (0.50-0.96), respectively. We also found a significantly interaction between the two SNPs, participants with rs1801133 - CT or TT and rs1801131 - AC or CC genotype have the lowest ALL risk, compared with participants with rs1801133 - CC and rs1801131 - AA genotype, OR (95% CI) was 0.32 (0.12-0.63). We did not find any haplotype between the rs1801133 and rs1801131 associated with ALL risk. rs1801133 and rs1801131 within MTHFR gene and their interaction were both associated with ALL risk in Chinese children.

Loading Tumor Hospital of Gansu Province collaborators
Loading Tumor Hospital of Gansu Province collaborators